Elicera Therapeutics AB
ELIC | ST
Overview
Corporate Details
- ISIN(s):
- SE0015382080 (+1 more)
- LEI:
- 549300I35L0R4INBFG27
- Country:
- Sweden
- Address:
- C/O Elicera Therapeutics AB, 402 24 Göteborg
- Website:
- https://elicera.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Elicera Therapeutics AB is a clinical-stage immuno-oncology company developing cell and gene therapies for cancer treatment. The company's approach is based on two technology types: CAR T-cell therapies and oncolytic viruses. Its proprietary iTANK (Immuno-Oncology TARgeting Killer-cells) platform is a universal technology designed to enhance any CAR T-cell therapy by stimulating a parallel, multi-targeted immune response against cancer, with a particular focus on solid tumors. Elicera's product portfolio includes four drug candidates. Its oncolytic virus, ELC-100, is in a Phase I/II clinical trial for neuroendocrine tumors, and its CAR T-cell therapy, ELC-301, is being prepared for a Phase I/II trial for B-cell lymphoma.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Elicera Therapeutics AB.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| No filings match the current criteria. | ||||
Automate Your Workflow. Get a real-time feed of all Elicera Therapeutics AB filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Elicera Therapeutics AB via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-03-11 | Margareth Jorvid | Other | Other | 21,700 | 40,145.00 SEK |
